Within the clinical trial encounter with Xyrem in narcolepsy/cataplexy patients at therapeutic doses, two sufferers reported stress and one documented sleeplessness subsequent abrupt discontinuation on the termination from the clinical trial; in The 2 clients with stress, the frequency of cataplexy